WO2012165914A3 - Novel diphenylmethane derivatives as sglt2 inhibitors - Google Patents

Novel diphenylmethane derivatives as sglt2 inhibitors Download PDF

Info

Publication number
WO2012165914A3
WO2012165914A3 PCT/KR2012/004366 KR2012004366W WO2012165914A3 WO 2012165914 A3 WO2012165914 A3 WO 2012165914A3 KR 2012004366 W KR2012004366 W KR 2012004366W WO 2012165914 A3 WO2012165914 A3 WO 2012165914A3
Authority
WO
WIPO (PCT)
Prior art keywords
compound
present
sglt2 inhibitors
diphenylmethane derivatives
preventing
Prior art date
Application number
PCT/KR2012/004366
Other languages
French (fr)
Other versions
WO2012165914A2 (en
Inventor
Soongyu Choi
Kwang-Seop Song
Suk Ho Lee
Min Ju Kim
Hee Jeong Seo
Eun-Jung Park
Younggyu Kong
So Ok PARK
Hyunku KANG
Myung Eun Jung
Kinam LEE
Hyun Jung Kim
Jun Sung Lee
Min Woo Lee
Mi-Soon Kim
Dong Ho Hong
Misuk KANG
Original Assignee
Green Cross Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corporation filed Critical Green Cross Corporation
Priority to EP12793162.4A priority Critical patent/EP2714032B1/en
Priority to CN201280026961.9A priority patent/CN103596564B/en
Priority to US14/122,836 priority patent/US9034921B2/en
Priority to JP2014513449A priority patent/JP5876570B2/en
Priority to KR1020137035066A priority patent/KR101576589B1/en
Priority to ES12793162T priority patent/ES2719656T3/en
Publication of WO2012165914A2 publication Critical patent/WO2012165914A2/en
Publication of WO2012165914A3 publication Critical patent/WO2012165914A3/en
Priority to US14/593,071 priority patent/US9371303B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

The present invention relates to a compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes. The present invention also provides a method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound.
PCT/KR2012/004366 2011-06-01 2012-06-01 Novel diphenylmethane derivatives as sglt2 inhibitors WO2012165914A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP12793162.4A EP2714032B1 (en) 2011-06-01 2012-06-01 Novel diphenylmethane derivatives as sglt2 inhibitors
CN201280026961.9A CN103596564B (en) 2011-06-01 2012-06-01 As the diphenylmethane derivatives of SGLT2 inhibitor
US14/122,836 US9034921B2 (en) 2011-06-01 2012-06-01 Diphenylmethane derivatives as SGLT2 inhibitors
JP2014513449A JP5876570B2 (en) 2011-06-01 2012-06-01 Novel diphenylmethane derivatives as SGLT2 inhibitors
KR1020137035066A KR101576589B1 (en) 2011-06-01 2012-06-01 Novel diphenylmethane derivatives as sglt2 inhibitors
ES12793162T ES2719656T3 (en) 2011-06-01 2012-06-01 Novel diphenylmethane derivatives as SGLT2 inhibitors
US14/593,071 US9371303B2 (en) 2011-06-01 2015-01-09 Diphenylmethane derivatives as SGLT2 inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161492143P 2011-06-01 2011-06-01
US61/492,143 2011-06-01

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/122,836 A-371-Of-International US9034921B2 (en) 2011-06-01 2012-06-01 Diphenylmethane derivatives as SGLT2 inhibitors
US14/593,071 Division US9371303B2 (en) 2011-06-01 2015-01-09 Diphenylmethane derivatives as SGLT2 inhibitors

Publications (2)

Publication Number Publication Date
WO2012165914A2 WO2012165914A2 (en) 2012-12-06
WO2012165914A3 true WO2012165914A3 (en) 2013-03-28

Family

ID=47260120

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/004366 WO2012165914A2 (en) 2011-06-01 2012-06-01 Novel diphenylmethane derivatives as sglt2 inhibitors

Country Status (8)

Country Link
US (2) US9034921B2 (en)
EP (1) EP2714032B1 (en)
JP (1) JP5876570B2 (en)
KR (1) KR101576589B1 (en)
CN (1) CN103596564B (en)
ES (1) ES2719656T3 (en)
TR (1) TR201903445T4 (en)
WO (1) WO2012165914A2 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103596564B (en) * 2011-06-01 2016-05-04 株式会社绿十字 As the diphenylmethane derivatives of SGLT2 inhibitor
US9012412B2 (en) * 2013-03-11 2015-04-21 Janssen Pharmaceutica Nv Dual SGLT1/SGLT2 inhibitors
US9340521B2 (en) * 2013-03-18 2016-05-17 Green Cross Corporation Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives
CN107311992B (en) * 2013-09-09 2020-08-18 上海研健新药研发有限公司 C-aryl glucoside derivative, preparation method and application thereof in medicine
US20160237054A1 (en) * 2013-09-27 2016-08-18 Sun Pharmaceutical Industries Limited Process for the purification of dapagliflozin
WO2015051484A1 (en) 2013-10-12 2015-04-16 Theracos, Inc. Preparation of hydroxy-benzylbenzene derivatives
CN104327027B (en) * 2014-10-14 2017-04-05 中国药科大学 One class novel C aryl glucoside SGLT2 inhibitor
CN107205925B (en) 2014-12-22 2020-12-11 阿雷斯贸易股份有限公司 Liquid pharmaceutical composition
CN104478674B (en) * 2015-01-15 2016-03-09 佛山市赛维斯医药科技有限公司 One class alkoxyphenyl radical propanediol derivative and purposes
CN104478675B (en) * 2015-01-15 2016-01-06 佛山市赛维斯医药科技有限公司 One class contains derivative and the purposes of alkoxyphenyl radical and fluoroform phenyl propylene glycol structure
CN104478671B (en) * 2015-01-15 2016-03-09 佛山市赛维斯医药科技有限公司 The two alkoxyphenyl radical propanediol derivative of one class and purposes
NZ743987A (en) * 2016-01-04 2019-10-25 Je Il Pharmaceutical Co Ltd C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same
MX2021008988A (en) * 2016-06-17 2022-05-05 Daewoong Pharmaceutical Co Ltd Method for producing diphenylmethane derivative.
KR101770302B1 (en) * 2016-06-28 2017-08-22 주식회사 녹십자 Method for preparing diphenylmethane derivatives
US10815210B2 (en) 2016-11-10 2020-10-27 Janssen Pharmaceutica Nv Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators
CN108203432B (en) * 2016-12-20 2021-03-02 宜昌东阳光长江药业股份有限公司 Glucopyranosyl derivative and application thereof in medicine
WO2018138050A1 (en) 2017-01-26 2018-08-02 Bayer Aktiengesellschaft Condensed bicyclic heterocyclene derivatives as pest control agents
WO2018155970A1 (en) * 2017-02-24 2018-08-30 동아에스티 주식회사 Novel glucose derivative as sglt-2 inhibitor
US10696662B2 (en) 2017-08-21 2020-06-30 Janssen Pharmaceutica Nv 5-fluoro-C-(aryl or heterocyclyl)-glycoside derivatives useful as dual SGLT1 / SGLT2 modulators
US11661406B2 (en) 2018-08-13 2023-05-30 Daewoong Pharmaceutical Co., Ltd. Method for producing intermediate useful for synthesis of SGLT inhibitor
JP2022028986A (en) * 2018-12-17 2022-02-17 株式会社トクヤマ Method for producing c-arylhydroxy glycoxide derivative
WO2020151623A1 (en) * 2019-01-24 2020-07-30 北京盈科瑞创新药物研究有限公司 Compound, preparation method therefor, and medical uses of intermediate thereof
CN110156791A (en) * 2019-06-11 2019-08-23 南京新酶合医药科技有限公司 The preparation of (5- tosyl -5H- pyrrolo- [2,3-b] pyrazine -2- base) t-butyl carbamate
CN112341416A (en) * 2019-08-09 2021-02-09 天津津艺医药科技发展有限责任公司 Method for preparing benzo oxygen-containing aliphatic heterocyclic derivative
CA3158593A1 (en) * 2019-12-03 2021-06-10 Seung Yup Paek Sphingosine-1-phosphate receptor agonist, preparation method therefor, and pharmaceutical composition containing same as active ingredient
CN111269205B (en) * 2020-02-19 2023-05-26 华侨大学 Preparation method of C-aryl glycoside compound
AU2021225706A1 (en) * 2020-02-27 2022-09-01 Daewoong Pharmaceutical Co., Ltd. Intermediate useful for synthesis of SGLT inhibitor and method for preparing SGLT inhibitor using same
CN112094253B (en) * 2020-09-10 2023-01-10 株式会社大熊制药 Synthetic method for preparing SGLT inhibitor intermediate
BR112023004425A2 (en) * 2020-09-10 2023-04-11 Daewoong Pharmaceutical Co Ltd METHOD FOR PREPARING COMPOUND 1 AND COMPOUND 2
JP2023551441A (en) * 2020-11-19 2023-12-08 ベイジン・インクリーズ・イノベーティブ・ドラッグ・カンパニー，リミテッド Glycoside derivatives and their production methods and applications
KR102427225B1 (en) * 2020-12-04 2022-08-01 주식회사 대웅테라퓨틱스 Pharmaceutical composition comprising sglt-2 inhibitor for preventing or treating diabetic opthalmopathy disease
EP4342476A1 (en) * 2021-05-21 2024-03-27 Daewoong Pharmaceutical Co., Ltd. Pharmaceutical composition for preventing or treating diabetes mellitus in animal of family canidae, comprising enavogliflozin
KR20230046784A (en) * 2021-09-30 2023-04-06 주식회사 대웅제약 Pharmaceutical composition comprising enavogliflozin
CN113801010A (en) * 2021-11-18 2021-12-17 山东诚创蓝海医药科技有限公司 Preparation method of 5-bromo-2-chlorobenzoic acid
CN113912487A (en) * 2021-11-23 2022-01-11 山东研峰新材料科技有限公司 Synthesis method of 2, 5-bis-halogenated benzoic acid
KR20230110001A (en) 2022-01-14 2023-07-21 주식회사 대웅제약 A method of preparing intermediates useful for the synthesis of SGLT inhibitors
KR20230112426A (en) * 2022-01-20 2023-07-27 주식회사 대웅제약 Pharmaceutical composition for preventing or treating obesity in canine animals containing enavogliflozin
KR20240035374A (en) 2022-09-08 2024-03-15 주식회사 대웅제약 A pharmaceutical composition comprising a metabolite of enavogliflozin and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011048112A1 (en) * 2009-10-20 2011-04-28 Novartis Ag Glycoside derivatives and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
RS53365B (en) * 2003-08-01 2014-10-31 Mitsubishi Tanabe Pharma Corporation Novel compounds having inhibitory activity against sodium-dependant transporter
AU2005219779B2 (en) * 2004-03-04 2011-04-14 Kissei Pharmaceutical Co., Ltd. Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
DE102004012676A1 (en) * 2004-03-16 2005-10-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg New glucopyranosyl-substituted benzene derivatives are sodium-dependent glucose cotransporter inhibitors, useful for treating e.g. metabolic disorders (type 1 and type 2 diabetes mellitus or metabolic acidosis)
TW200637839A (en) * 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
AR053329A1 (en) * 2005-01-31 2007-05-02 Tanabe Seiyaku Co INDOL DERIVATIVES USEFUL AS INHIBITORS OF GLUCOSE CONVEYORS DEPENDENT ON SODIUM (SGLT)
US20080027014A1 (en) 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
WO2008020011A1 (en) * 2006-08-15 2008-02-21 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
TWI499414B (en) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc Inhibitors of sodium glucose co-transporter 2 and methods of their use
WO2008101939A1 (en) 2007-02-21 2008-08-28 Boehringer Ingelheim International Gmbh Tetrasubstituted glucopyranosylated benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
PL2183263T3 (en) 2007-07-26 2012-03-30 Lexicon Pharmaceuticals Inc Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
DE102008017590A1 (en) * 2008-04-07 2009-10-08 Merck Patent Gmbh Glucopyranosidderivate
CN101830876A (en) * 2009-03-12 2010-09-15 上海恒瑞医药有限公司 C-aryl glucoside derivative, preparation method thereof and application thereof in medicine
WO2010128152A1 (en) * 2009-05-07 2010-11-11 Novartis Ag Fused heterocyclic c-glycosides for the treatment of diabetes
KR101352934B1 (en) * 2009-06-19 2014-02-19 주식회사 녹십자 Novel c-aryl glucoside sglt2 inhibitors and pharmaceutical composition comprising same
WO2011048148A2 (en) * 2009-10-20 2011-04-28 Novartis Ag Glycoside derivative and uses thereof
WO2011107494A1 (en) * 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
US8586550B2 (en) * 2010-06-18 2013-11-19 Green Cross Corporation Thiazole derivatives as SGLT2 inhibitors and pharmaceutical composition comprising same
US8614195B2 (en) 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
CA2832951A1 (en) * 2011-04-14 2012-10-18 Novartis Ag Glycoside derivatives and uses thereof
CN103596564B (en) * 2011-06-01 2016-05-04 株式会社绿十字 As the diphenylmethane derivatives of SGLT2 inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011048112A1 (en) * 2009-10-20 2011-04-28 Novartis Ag Glycoside derivatives and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KANG, S. Y. ET AL.: "Glucosides with cyclic diarylpolynoid as novel C-aryl glucoside SGLT2 inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 21, no. 12, 28 April 2011 (2011-04-28), pages 3759 - 3763, XP028091106 *

Also Published As

Publication number Publication date
ES2719656T3 (en) 2019-07-11
KR20140022086A (en) 2014-02-21
US20140088079A1 (en) 2014-03-27
EP2714032A2 (en) 2014-04-09
EP2714032A4 (en) 2015-05-06
EP2714032B1 (en) 2019-01-16
JP2014515396A (en) 2014-06-30
US9034921B2 (en) 2015-05-19
JP5876570B2 (en) 2016-03-02
US9371303B2 (en) 2016-06-21
CN103596564A (en) 2014-02-19
US20150152075A1 (en) 2015-06-04
CN103596564B (en) 2016-05-04
TR201903445T4 (en) 2019-03-21
WO2012165914A2 (en) 2012-12-06
KR101576589B1 (en) 2015-12-10

Similar Documents

Publication Publication Date Title
WO2012165914A3 (en) Novel diphenylmethane derivatives as sglt2 inhibitors
WO2011159067A3 (en) Thiazole derivatives as sglt2 inhibitors and pharmaceutical composition comprising same
WO2010147430A3 (en) Novel c-aryl glucoside sglt2 inhibitors and pharmaceutical composition comprising same
MX342665B (en) Crystalline form of benzylbenzene sglt2 inhibitor.
EP1932530A4 (en) Agent for enhancing collagen production and utilization of the same
EP3318562A3 (en) Benzylbenzene derivatives and methods of use
WO2007140191A3 (en) Glucose transport inhibitors and methods of use
WO2012033390A3 (en) Novel thiophene derivative as sglt2 inhibitor and pharmaceutical composition comprising same
WO2013091775A3 (en) Use of cyclohexanol derivatives as antimicrobial active ingredients
WO2010043682A3 (en) Process for the preparation of compounds useful as inhibitors of sglt
EA201300550A1 (en) PHARMACEUTICAL COMPOSITION, METHODS OF TREATMENT AND THEIR APPLICATION
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
WO2012083122A8 (en) Inhibitors of influenza viruses replication
MX345494B (en) Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient.
WO2006099941A8 (en) Aminocarbonyl-substituted 8-n-benzimidazoles, method for their production and their use as medicaments
NZ707859A (en) Inhibitors of sodium glucose cotransporter 1
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
WO2011012816A3 (en) Pharmaceutical formulation
WO2011147951A8 (en) Cycloamino derivatives as gpr119 agonists
WO2008070268A3 (en) Pharmaceutical compositions
WO2010095768A8 (en) 4 -isopropylphenyl glucitol compounds as sglt1 inhibitors
WO2010132757A3 (en) Antibacterial aminoglycoside analogs
EA201001575A1 (en) EMULIGUIVE CONCENTRATE
WO2010094837A3 (en) Sugar product
WO2011159124A3 (en) Novel benzoxazole derivative having inhibitory activity against interleukin-6, preparation method thereof, and pharmaceutical composition containing same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201280026961.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12793162

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14122836

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2014513449

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20137035066

Country of ref document: KR

Kind code of ref document: A